DSpace Collection:

Plasma ApoA-1 and endothelin-1 levels changes in early Parkinson disease and its relationship with cognitive function and cerebral white matter structure change

Sat, 16 Jan 2021 00:00:00 GMT

Title: Plasma ApoA-1 and endothelin-1 levels changes in early Parkinson disease and its relationship with cognitive function and cerebral white matter structure change Authors: Yan, Yingying; Fu, Jianjiong Abstract: The study aimed to investigate the plasma apolipoprotein A-1 (ApoA-1) and endothelin -1 (ET-1) changes in early Parkinson disease (PD), and analyze their relationship with cognitive function and cerebral white matter structure (WMS) change. 76 early PD patients were selected as group PD, and 30 cases of healthy persons were selected as control group. They all scanned with magnetic resonance imaging (MRI) diffusion tensor. The ApoA-1, ET-1, WMS changes, and Montreal Cognitive Assessment (MoCA) scores were recorded in the two groups of subjects. The results revealed that ApoA-1 level and Mo CA score in PD group decreased, FA value in bilateral temporal lobe, left anterior cingulate tract, corpus callosum, and other cerebral WMS area in PD group were also decreased, and ET-1 level in PD group increased (P<0.05). Compared with those of PD group patients with Mo CA≥26, plasma ApoA-1 levels and cerebral WMS FA values of the patients with Mo CA＜26 were decreased, (P<0.05); the MoCA score of PD group was positively correlated with the cerebral WMS FA values (P<0.05). In short, the ApoA-1 level in patients with early PD decreased, while the ET-1 level increased, and both were related to cognitive function and WMS.

Therapeutic effect of gefitinib on patients with advanced EGFRmutation NSCLC

Sat, 16 Jan 2021 00:00:00 GMT

Title: Therapeutic effect of gefitinib on patients with advanced EGFRmutation NSCLC Authors: Xu, Ailing; Yan, Haixia; Bu, Tongliang Abstract: This study aims to study the role of gefitinib on patients with advanced EGFR-mutation NSCLC (Non-Small Cell Lung Cancer). Totally 115 patients with advanced EGFR-mutation NSCLC treated in our hospital were enrolled as research objects. They were randomly divided into control group (n=57) applied with cisplatin + pemetrexed and experimental group (n=58) subject to gefitinib+ cisplatin + pemetrexed, both groups were applied with treatment for 4 cycles. Clinical efficacy: The disease control rate (DCR) was 72.41% in the experimental group, which was higher than that of the control group (54.39%, p<0.05); Serum CEA, CYFRA21-1, MMP-9 levels: after 2 and 4 cycles of treatment, serum CEA, CYFRA21-1, and MMP-9 levels were lower in the experimental group (p<0.05); Immune function: after 2 and 4 cycles of treatment, Th1 cells and Th1/Th2 cell levels were higher in the experimental group, while Th2 cell level was higher in the control group (p<0.05); Angiogenesis related indicators: the levels of VEGF, HIF-1α and sCD105 were lower in the experimental group after 2 and 4 cycles of treatment (p<0.05); (5) Adverse reactions: After 2 and 4 cycles of treatment, the levels of VEGF, HIF-1α, and sCD105 were lower in the experimental group (p<0.05). The application of gefitinib in patients with advanced EGFR-mutation NSCLC can help down-regulate CEA, CYFRA21-1, and MMP-9 levels, inhibit angiopoiesis, enhance immune function, and increase disease control rate.

Development, characterization and evaluation of in-vitro anti-inflammatory activity of ginger extract based micro emulsion

Sat, 16 Jan 2021 00:00:00 GMT

Title: Development, characterization and evaluation of in-vitro anti-inflammatory activity of ginger extract based micro emulsion Authors: Akram, Ayesha; Rasul, Akhtar; Waqas, Muhammad Khurram; Irfan, Muhammad; Khalid, Syed Haroon; Aamir, Muhammad Naeem; Ghulam Murtaza; Kashif Ur Rehman; Iqbal, Muhammad; Khan, Barkat Ali Abstract: Zingeber officinale is a commonly used plant which has been shown to possess anti-inflammatory activity. The active compounds present in ginger are gingerols, shagaols and paradol. The aim of this study was formulation of topical microemulsion system to enhance the solubility and stability of ginger extract, as it is unstable in the presence of light, air, heat and long term storage, and to evaluate its anti-inflammatory activity. The solubility of ginger extract in different oils, surfactants, and co-surfactants was determined in order to find the optimal components for microemulsion. IPM was selected as oil phase, tween 80 and PEG 400 were selected as surfactant and co-surfactant respectively based on highest solubility values. Pseudo-ternary phase diagram was constructed in order to find out the microemulsion region. The prepared microemulsions were evaluated for pH, viscosity, conductivity, refractive index, globular size, zeta potential, polydispersity index, ginger extract content. The formulation F1 showed best physicochemical properties with smallest globular size. It also showed significant (p<0.05) anti-inflammatory effect as compared to reference piroxicam drug solution. Based on the results, it is concluded that ginger extract can be used to develop stable microemulsion system and promising anti-inflammatory activity.

Application effect of tirofiban on percutaneous coronary intervention in patients with acute coronary syndrome and its postoperative effect on C-X-C motif chemokine ligand 16 level and myocardial perfusion

Sat, 16 Jan 2021 00:00:00 GMT

Title: Application effect of tirofiban on percutaneous coronary intervention in patients with acute coronary syndrome and its postoperative effect on C-X-C motif chemokine ligand 16 level and myocardial perfusion Authors: Xu, Maoling; Zhang, Cun; Yu, Xiuzhen; Zhu, Lele; Tan, Hong; Wang, Cong; Zhao, Lingshi; Zhao, Zhihua Abstract: : This study aimed to investigate the application effect of tirofiban on percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) and its postoperative effect on C-X-C motif chemokine ligand 16 (CXCL16) level and myocardial perfusion. A total of 50 cases of patients diagnosed with acute coronary syndrome and treated in Sunshine Union Hospital (Weifang, China) were included in group A and 30 cases of healthy subjects underwent physical examination in our hospital during the same period were enrolled in group B. Tirofiban was used in group A patients during PCI. Clinical efficacy evaluation criteria were used to evaluate the efficacy after treatment. The level of CXCL16 in serum before and after treatment was detected by qRT-PCR. Receiver operating characteristic (ROC) curve was drawn to analyze the value of C-X-C Motif Chemokine Ligand in diagnosing ACS. Before treatment, CXCL16 level in group A was significantly higher than that in group B (p<0.001). After treatment, patients in TMPG grade 3 in group A were significantly increased (p<0.001). Tirofiban could improve myocardial perfusion in patients with ACS after PCI, reduce adverse events and CXCL16 levels. Serum CXCL16 is expected to be a potential diagnostic and therapeutic predictor of ACS.